Search

Your search keyword '"Bettelheim, Peter"' showing total 259 results
Start Over Author "Bettelheim, Peter"
259 results on '"Bettelheim, Peter"'

1. CAR virus receptor mediates erythroid differentiation and migration and is downregulated in MDS

Author

Bauer, Karin, Machherndl-Spandl, Sigrid, Kazianka, Lukas, Sadovnik, Irina, Gültekin, Sinan, Suessner, Susanne, Proell, Johannes, Lauf, Jeroen, Hoermann, Gregor, Eisenwort, Gregor, Häfner, Norman, Födermayr-Mayrleitner, Mathilde, Schmolke, Ann-Sofie, van der Kouwe, Emiel, Platzbecker, Uwe, Lion, Thomas, Weltermann, Ansgar, Zach, Otto, Webersinke, Gerald, Germing, Ulrich, Gabriel, Christian, Sperr, Wolfgang R., Béné, Marie C., Staber, Philipp B., Bettelheim, Peter, and Valent, Peter

Published
2023
Full Text
View/download PDF

5. The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML): A representative and useful real-life data source for further biomedical research

Author

Geissler, Klaus, Jäger, Eva, Barna, Agnes, Gurbisz, Michael, Marschon, Renate, Graf, Temeida, Graf, Elmir, Borjan, Bojana, Jilch, Ruth, Geissler, Christoph, Hoermann, Gregor, Esterbauer, Harald, Schwarzinger, Ilse, Nösslinger, Thomas, Pfeilstöcker, Michael, Tüchler, Heinz, Reisner, Regina, Sliwa, Thamer, Keil, Felix, Bettelheim, Peter, Machherndl-Spandl, Sigrid, Doleschal, Bernhard, Zach, Otto, Weltermann, Ansgar, Heibl, Sonja, Thaler, Josef, Zebisch, Armin, Sill, Heinz, Stauder, Reinhard, Webersinke, Gerald, Petzer, Andreas, Kusec, Rajko, Ulsperger, Ernst, Schneeweiss, Bruno, Berger, Jörg, Öhler, Leopold, Germing, Ulrich, Sperr, Wolfgang R., Knöbl, Paul, Jäger, Ulrich, and Valent, Peter

Published
2019
Full Text
View/download PDF

6. Phenotypic characterization of disease‐initiating stem cells in JAK2 ‐ or CALR ‐mutated myeloproliferative neoplasms

Author

Ivanov, Daniel, primary, Milosevic Feenstra, Jelena D., additional, Sadovnik, Irina, additional, Herrmann, Harald, additional, Peter, Barbara, additional, Willmann, Michael, additional, Greiner, Georg, additional, Slavnitsch, Katharina, additional, Hadzijusufovic, Emir, additional, Rülicke, Thomas, additional, Dahlhoff, Maik, additional, Hoermann, Gregor, additional, Machherndl‐Spandl, Sigrid, additional, Eisenwort, Gregor, additional, Fillitz, Michael, additional, Sliwa, Thamer, additional, Krauth, Maria‐Theresa, additional, Bettelheim, Peter, additional, Sperr, Wolfgang R., additional, Koller, Elisabeth, additional, Pfeilstöcker, Michael, additional, Gisslinger, Heinz, additional, Keil, Felix, additional, Kralovics, Robert, additional, and Valent, Peter, additional

Published
2023
Full Text
View/download PDF

7. Multiparameter flow cytometry in the evaluation of myelodysplasia:Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group

Author

Porwit, Anna, Béné, Marie C., Duetz, Carolien, Matarraz, Sergio, Oelschlaegel, Uta, Westers, Theresia M., Wagner-Ballon, Orianne, Kordasti, Shahram, Valent, Peter, Preijers, Frank, Alhan, Canan, Bellos, Frauke, Bettelheim, Peter, Burbury, Kate, Chapuis, Nicolas, Cremers, Eline, Della Porta, Matteo G., Dunlop, Alan, Eidenschink-Brodersen, Lisa, Font, Patricia, Fontenay, Michaela, Hobo, Willemijn, Ireland, Robin, Johansson, Ulrika, Loken, Michael R., Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Saft, Leonie, Subira, Dolores, te Marvelde, Jeroen, Wells, Denise A., van der Velden, Vincent H.J., Kern, Wolfgang, van de Loosdrecht, Arjan A., Porwit, Anna, Béné, Marie C., Duetz, Carolien, Matarraz, Sergio, Oelschlaegel, Uta, Westers, Theresia M., Wagner-Ballon, Orianne, Kordasti, Shahram, Valent, Peter, Preijers, Frank, Alhan, Canan, Bellos, Frauke, Bettelheim, Peter, Burbury, Kate, Chapuis, Nicolas, Cremers, Eline, Della Porta, Matteo G., Dunlop, Alan, Eidenschink-Brodersen, Lisa, Font, Patricia, Fontenay, Michaela, Hobo, Willemijn, Ireland, Robin, Johansson, Ulrika, Loken, Michael R., Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Saft, Leonie, Subira, Dolores, te Marvelde, Jeroen, Wells, Denise A., van der Velden, Vincent H.J., Kern, Wolfgang, and van de Loosdrecht, Arjan A.

Abstract

Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic syndrome (MDS). MFC can also be applied in the follow-up of MDS patients undergoing treatment. This document summarizes recommendations from the International/European Leukemia Net Working Group for Flow Cytometry in Myelodysplastic Syndromes (ELN iMDS Flow) on the analytical issues in MFC for the diagnostic work-up of MDS. Recommendations for the analysis of several BM cell subsets such as myeloid precursors, maturing granulocytic and monocytic components and erythropoiesis are given. A core set of 17 markers identified as independently related to a cytomorphologic diagnosis of myelodysplasia is suggested as mandatory for MFC evaluation of BM in a patient with cytopenia. A myeloid precursor cell (CD34+CD19−) count >3% should be considered immunophenotypically indicative of myelodysplasia. However, MFC results should always be evaluated as part of an integrated hematopathology work-up. Looking forward, several machine-learning-based analytical tools of interest should be applied in parallel to conventional analytical methods to investigate their usefulness in integrated diagnostics, risk stratification, and potentially even in the evaluation of response to therapy, based on MFC data. In addition, compiling large uniform datasets is desirable, as most of the machine-learning-based methods tend to perform better with larger numbers of investigated samples, especially in such a heterogeneous disease as MDS.

Published
2023

8. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group

Author

Porwit, Anna, Béne, Marie C., Duetz, Carolien, Matarraz, Sergio, Oelschlaegel, Uta, Westers, Theresia M., Wagner-Ballon, Orianne, Kordasti, Sharham, Valent, Peter, Preijers, Frank W. M. B., Alhan, Canan, Bellos, Frauke, Bettelheim, Peter, Burbury, Kate, Chapuis, Nicolas, Cremers, Eline M. P., Della Porta, Matteo G., Dunlop, Alan, Eidenschink Brodersen, Lisa, Font, Patricia, Fontenay, Michaela, Hobo, Willemijn, Ireland, Robin, Johansson, Ulrika, Loken, Michael R., Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Saft, Leonie, Subirá, Dolores, Marvelde, Jeroen G. te, Wells, Denise A., Velden, Vincent H. J. van der, Kern, Wolfgang, Loosdrecht, Arjan A. Van De, Porwit, Anna, Béne, Marie C., Duetz, Carolien, Matarraz, Sergio, Oelschlaegel, Uta, Westers, Theresia M., Wagner-Ballon, Orianne, Kordasti, Sharham, Valent, Peter, Preijers, Frank W. M. B., Alhan, Canan, Bellos, Frauke, Bettelheim, Peter, Burbury, Kate, Chapuis, Nicolas, Cremers, Eline M. P., Della Porta, Matteo G., Dunlop, Alan, Eidenschink Brodersen, Lisa, Font, Patricia, Fontenay, Michaela, Hobo, Willemijn, Ireland, Robin, Johansson, Ulrika, Loken, Michael R., Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Saft, Leonie, Subirá, Dolores, Marvelde, Jeroen G. te, Wells, Denise A., Velden, Vincent H. J. van der, Kern, Wolfgang, and Loosdrecht, Arjan A. Van De

Abstract

Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic syndrome (MDS). MFC can also be applied in the follow-up of MDS patients undergoing treatment. This document summarizes recommendations from the International/European Leukemia Net Working Group for Flow Cytometry in Myelodysplastic Syndromes (ELN iMDS Flow) on the analytical issues in MFC for the diagnostic work-up of MDS. Recommendations for the analysis of several BM cell subsets such as myeloid precursors, maturing granulocytic and monocytic components and erythropoiesis are given. A core set of 17 markers identified as independently related to a cytomorphologic diagnosis of myelodysplasia is suggested as mandatory for MFC evaluation of BM in a patient with cytopenia. A myeloid precursor cell (CD34+CD19−) count >3% should be considered immunophenotypically indicative of myelodysplasia. However, MFC results should always be evaluated as part of an integrated hematopathology work-up. Looking forward, several machine-learning-based analytical tools of interest should be applied in parallel to conventional analytical methods to investigate their usefulness in integrated diagnostics, risk stratification, and potentially even in the evaluation of response to therapy, based on MFC data. In addition, compiling large uniform datasets is desirable, as most of the machine-learning-based methods tend to perform better with larger numbers of investigated samples, especially in such a heterogeneous disease as MDS.

Published
2023

9. Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group

Author

Kern, Wolfgang, Westers, Theresia M., Bellos, Frauke, Bene, Marie Christine, Bettelheim, Peter, Eidenschink Brodersen, Lisa, Burbury, Kate, Chu, Sung-Chao, Cullen, Matthew, Della Porta, Matteo G., Dunlop, Alan, Johansson, Ulrika, Matarraz, Sergio, Oelschlaegel, Uta, Ogata, Kiyoyuki, Porwit, Anna, Preijers, Frank W. M. B., Psarra, Katherina, Saft, Leonie, Subirá, Dolores, Weiß, Elisabeth, Velden, Vincent H. J. van der, Loosdrecht, Arjan A. Van De, Kern, Wolfgang, Westers, Theresia M., Bellos, Frauke, Bene, Marie Christine, Bettelheim, Peter, Eidenschink Brodersen, Lisa, Burbury, Kate, Chu, Sung-Chao, Cullen, Matthew, Della Porta, Matteo G., Dunlop, Alan, Johansson, Ulrika, Matarraz, Sergio, Oelschlaegel, Uta, Ogata, Kiyoyuki, Porwit, Anna, Preijers, Frank W. M. B., Psarra, Katherina, Saft, Leonie, Subirá, Dolores, Weiß, Elisabeth, Velden, Vincent H. J. van der, and Loosdrecht, Arjan A. Van De

Abstract

[Background]: Myelodysplastic syndromes (MDS) represent a diagnostic challenge. This prospective multicenter study was conducted to evaluate pre-defined flow cytometric markers in the diagnostic work-up of MDS and chronic myelomonocytic leukemia (CMML). [Methods]: Thousand six hundred and eighty-two patients with suspected MDS/CMML were analyzed by both cytomorphology according to WHO 2016 criteria and flow cytometry according to ELN recommendations. Flow cytometric readout was categorized ‘non-MDS’ (i.e. no signs of MDS/CMML and limited signs of MDS/CMML) and ‘in agreement with MDS’ (i.e., in agreement with MDS/CMML). [Results]: Flow cytometric readout categorized 60% of patients in agreement with MDS, 28% showed limited signs of MDS and 12% had no signs of MDS. In 81% of cases flow cytometric readouts and cytomorphologic diagnosis correlated. For high-risk MDS, the level of concordance was 92%. A total of 17 immunophenotypic aberrancies were found independently related to MDS/CMML in ≥1 of the subgroups of low-risk MDS, high-risk MDS, CMML. A cut-off of ≥3 of these aberrancies resulted in 80% agreement with cytomorphology (20% cases concordantly negative, 60% positive). Moreover, >3% myeloid progenitor cells were significantly associated with MDS (286/293 such cases, 98%). [Conclusion]: Data from this prospective multicenter study led to recognition of 17 immunophenotypic markers allowing to identify cases ‘in agreement with MDS’. Moreover, data emphasizes the clinical utility of immunophenotyping in MDS diagnostics, given the high concordance between cytomorphology and the flow cytometric readout. Results from the current study challenge the application of the cytomorphologically defined cut-off of 5% blasts for flow cytometry and rather suggest a 3% cut-off for the latter.

Published
2023

10. Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues—Recommendations from the European LeukemiaNet

Author

Austrian Science Fund, European Commission, Velden, Vincent H. J. van der, Preijers, Frank W. M. B., Johansson, Ulrika, Westers, Theresia M., Dunlop, Alan, Porwit, Anna, Béne, Marie C., Valent, Peter, Marvelde, Jeroen G. te, Wagner-Ballon, Orianne, Oelschlaegel, Uta, Saft, Leonie, Kordasti, Sharham, Ireland, Robin, Cremers, Eline M. P., Alhan, Canan, Duetz, Carolien, Hobo, Willemijn, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink Brodersen, Lisa, Font, Patricia, Loken, Michael R., Matarraz, Sergio, Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, Weiß, Elisabeth, Kern, Wolfgang, Austrian Science Fund, European Commission, Velden, Vincent H. J. van der, Preijers, Frank W. M. B., Johansson, Ulrika, Westers, Theresia M., Dunlop, Alan, Porwit, Anna, Béne, Marie C., Valent, Peter, Marvelde, Jeroen G. te, Wagner-Ballon, Orianne, Oelschlaegel, Uta, Saft, Leonie, Kordasti, Sharham, Ireland, Robin, Cremers, Eline M. P., Alhan, Canan, Duetz, Carolien, Hobo, Willemijn, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink Brodersen, Lisa, Font, Patricia, Loken, Michael R., Matarraz, Sergio, Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, Weiß, Elisabeth, and Kern, Wolfgang

Abstract

[Background]: Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. [Methods]: Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. [Results]: We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. [Conclusions]. These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.

Published
2023

11. ELN iMDS flow working group validation of the monocyte assay for chronic myelomonocytic leukemia diagnosis by flow cytometry

Author

Wagner-Ballon, Orianne, Bettelheim, Peter, Lauf, Jeroen, Bellos, Frauke, Della Porta, Matteo G., Travaglino, Erica, Subirá, Dolores, Nuevo Lopez, Irene, Tarfi, Sihem, Westers, Theresia M., Johansson, Ulrika, Psarra, Katherina, Karathanos, Serafeim, Matarraz, Sergio, Colado, Enrique, Gupta, Monali, Ireland, Robin, Kern, Wolfgang, Loosdrecht, Arjan A. Van De, Wagner-Ballon, Orianne, Bettelheim, Peter, Lauf, Jeroen, Bellos, Frauke, Della Porta, Matteo G., Travaglino, Erica, Subirá, Dolores, Nuevo Lopez, Irene, Tarfi, Sihem, Westers, Theresia M., Johansson, Ulrika, Psarra, Katherina, Karathanos, Serafeim, Matarraz, Sergio, Colado, Enrique, Gupta, Monali, Ireland, Robin, Kern, Wolfgang, and Loosdrecht, Arjan A. Van De

Abstract

[Background]: It was proposed that peripheral blood (PB) monocyte profiles evaluated by flow cytometry, called “monocyte assay,” could rapidly and efficiently distinguish chronic myelomonocytic leukemia (CMML) from other causes of monocytosis by highlighting an increase in the classical monocyte (cMo) fraction above 94%. However, the robustness of this assay requires a large multicenter validation and the assessment of its feasibility on bone marrow (BM) samples, as some centers may not have access to PB. [Methods]: PB and/or BM samples from patients displaying monocytosis were assessed with the “monocyte assay” by 10 ELN iMDS Flow working group centers with harmonized protocols. The corresponding files were reanalyzed in a blind fashion and the cMo percentages obtained by both analyses were compared. Confirmed diagnoses were collected when available. [Results]: The comparison between cMo percentages from 267 PB files showed a good global significant correlation (r = 0.88) with no bias. Confirmed diagnoses, available for 212 patients, achieved a 94% sensitivity and an 84% specificity. Hence, 95/101 CMML patients displayed cMo ≥94% while cMo <94% was observed in 83/99 patients with reactive monocytosis and in 10/12 patients with myeloproliferative neoplasms (MPN) with monocytosis. The established Receiver Operator Curve again provided a 94% cut-off value of cMo. The 117 BM files reanalysis led to an 87% sensitivity and an 80% specificity, with excellent correlation between the 43 paired samples to PB. [Conclusions]: This ELN multicenter study demonstrates the robustness of the monocyte assay with only limited variability of cMo percentages, validates the 94% cutoff value, confirms its high sensitivity and specificity in PB and finally, also confirms the possibility of its use in BM samples.

Published
2023

12. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome:A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

Author

van de Loosdrecht, Arjan A., Kern, Wolfgang, Porwit, Anna, Valent, Peter, Kordasti, Sharham, Cremers, Eline, Alhan, Canan, Duetz, Carolien, Dunlop, Alan, Hobo, Willemijn, Preijers, Frank, Wagner-Ballon, Orianne, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink-Brodersen, Lisa, Font, Patricia, Johansson, Ulrika, Loken, Michael R., te Marvelde, Jeroen G., Matarraz, Sergio, Ogata, Kiyoyuki, Oelschlaegel, Uta, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Béné, Marie C., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, van der Velden, Vincent H.J., Westers, Theresia M., Saft, Leonie, Ireland, Robin, van de Loosdrecht, Arjan A., Kern, Wolfgang, Porwit, Anna, Valent, Peter, Kordasti, Sharham, Cremers, Eline, Alhan, Canan, Duetz, Carolien, Dunlop, Alan, Hobo, Willemijn, Preijers, Frank, Wagner-Ballon, Orianne, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink-Brodersen, Lisa, Font, Patricia, Johansson, Ulrika, Loken, Michael R., te Marvelde, Jeroen G., Matarraz, Sergio, Ogata, Kiyoyuki, Oelschlaegel, Uta, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Béné, Marie C., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, van der Velden, Vincent H.J., Westers, Theresia M., Saft, Leonie, and Ireland, Robin

Abstract

This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.

Published
2023

13. Flow cytometric analysis of myelodysplasia:Pre-analytical and technical issues—Recommendations from the European LeukemiaNet

Author

van der Velden, Vincent H.J., Preijers, Frank, Johansson, Ulrika, Westers, Theresia M., Dunlop, Alan, Porwit, Anna, Béné, Marie C., Valent, Peter, te Marvelde, Jeroen, Wagner-Ballon, Orianne, Oelschlaegel, Uta, Saft, Leonie, Kordasti, Sharham, Ireland, Robin, Cremers, Eline, Alhan, Canan, Duetz, Carolien, Hobo, Willemijn, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenshink-Brodersen, Lisa, Font, Patricia, Loken, Michael R., Matarraz, Sergio, Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, Weiß, Elisabeth, Kern, Wolfgang, van de Loosdrecht, Arjan, van der Velden, Vincent H.J., Preijers, Frank, Johansson, Ulrika, Westers, Theresia M., Dunlop, Alan, Porwit, Anna, Béné, Marie C., Valent, Peter, te Marvelde, Jeroen, Wagner-Ballon, Orianne, Oelschlaegel, Uta, Saft, Leonie, Kordasti, Sharham, Ireland, Robin, Cremers, Eline, Alhan, Canan, Duetz, Carolien, Hobo, Willemijn, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenshink-Brodersen, Lisa, Font, Patricia, Loken, Michael R., Matarraz, Sergio, Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, Weiß, Elisabeth, Kern, Wolfgang, and van de Loosdrecht, Arjan

Abstract

Background: Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. Methods: Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. Results: We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. Conclusions: These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.

Published
2023

14. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

Author

European Commission, Loosdrecht, Arjan A. Van De, Kern, Wolfgang, Porwit, Anna, Valent, Peter, Kordasti, Sharham, Cremers, Eline M. P., Alhan, Canan, Duetz, Carolien, Dunlop, Alan, Hobo, Willemijn, Preijers, Frank W. M. B., Wagner-Ballon, Orianne, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink-Brodersen, Lisa, Font, Patricia, Johansson, Ulrika, Loken, Michael R., Marvelde, Jeroen G. te, Matarraz, Sergio, Ogata, Kiyoyuki, Oelschlaegel, Uta, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Béne, Marie C., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, Velden, Vincent H. J. van der, Westers, Theresia M., Saft, Leonie, Ireland, Robin, European Commission, Loosdrecht, Arjan A. Van De, Kern, Wolfgang, Porwit, Anna, Valent, Peter, Kordasti, Sharham, Cremers, Eline M. P., Alhan, Canan, Duetz, Carolien, Dunlop, Alan, Hobo, Willemijn, Preijers, Frank W. M. B., Wagner-Ballon, Orianne, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink-Brodersen, Lisa, Font, Patricia, Johansson, Ulrika, Loken, Michael R., Marvelde, Jeroen G. te, Matarraz, Sergio, Ogata, Kiyoyuki, Oelschlaegel, Uta, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Béne, Marie C., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, Velden, Vincent H. J. van der, Westers, Theresia M., Saft, Leonie, and Ireland, Robin

Abstract

This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.

Published
2023

15. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues

Author

Porwit, Anna, primary, Béné, Marie C., additional, Duetz, Carolien, additional, Matarraz, Sergio, additional, Oelschlaegel, Uta, additional, Westers, Theresia M., additional, Wagner‐Ballon, Orianne, additional, Kordasti, Shahram, additional, Valent, Peter, additional, Preijers, Frank, additional, Alhan, Canan, additional, Bellos, Frauke, additional, Bettelheim, Peter, additional, Burbury, Kate, additional, Chapuis, Nicolas, additional, Cremers, Eline, additional, Della Porta, Matteo G., additional, Dunlop, Alan, additional, Eidenschink‐Brodersen, Lisa, additional, Font, Patricia, additional, Fontenay, Michaela, additional, Hobo, Willemijn, additional, Ireland, Robin, additional, Johansson, Ulrika, additional, Loken, Michael R., additional, Ogata, Kiyoyuki, additional, Orfao, Alberto, additional, Psarra, Katherina, additional, Saft, Leonie, additional, Subira, Dolores, additional, te Marvelde, Jeroen, additional, Wells, Denise A., additional, van der Velden, Vincent H. J., additional, Kern, Wolfgang, additional, and van de Loosdrecht, Arjan A., additional

Published
2022
Full Text
View/download PDF

16. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

Author

Loosdrecht, Arjan, Kern, Wolfgang, Porwit, Anna, Valent, Peter, Kordasti, Sharham, Cremers, Eline, Alhan, Canan, Duetz, Carolien, Dunlop, Alan, Hobo, Willemijn, Preijers, Frank, Wagner‐ballon, Orianne, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink‐brodersen, Lisa, Font, Patricia, Johansson, Ulrika, Loken, Michael, Marvelde, Jeroen, Matarraz, Sergio, Ogata, Kiyoyuki, Oelschlaegel, Uta, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise, Béné, Marie, Della Porta, Matteo, Burbury, Kate, Bellos, Frauke, Velden, Vincent, Westers, Theresia, Saft, Leonie, Ireland, Robin, MUMC+: MA Med Staf Artsass Interne Geneeskunde (9), RS: FHML non-thematic output, Amsterdam UMC - Amsterdam University Medical Center, Munich Leukemia Laboratory [Munich, Germany] (M2L), Lund University [Lund], Medizinische Universität Wien = Medical University of Vienna, King‘s College London, Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht], The Royal Marsden, Radboud University Medical Center [Nijmegen], Hôpital Henri Mondor, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Ordensklinikum Linz Elisabethinen, HematoLogics, Inc. [Seattle, WA, USA], Hospital General Universitario 'Gregorio Marañón' [Madrid], University Hospitals Bristol, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Universidad de Salamanca, Metropolitan Research and Treatment Centre for Blood Disorders [Tokyo, Japan] (MRTC Japan), University Hospital Carl Gustav Carus [Dresden, Germany], Technische Universität Dresden = Dresden University of Technology (TU Dresden), Evangelismos Athens General Hospital, Universidad de Guadalajara, Immunobiology of Human αβ and γδ T Cells and Immunotherapeutic Applications (CRCINA-ÉQUIPE 1), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre hospitalier universitaire de Nantes (CHU Nantes), Humanitas University [Milan] (Hunimed), Istituto Clinico Humanitas [Milan] (IRCCS Milan), University of Melbourne, Karolinska Institutet [Stockholm], King's College Hospital (KCH), Hematology, CCA - Cancer biology and immunology, Internal medicine, Hematology laboratory, Immunology, and Bernardo, Elizabeth

Subjects
standardization, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], flow cytometry, CONSORTIUM, [SDV.CAN]Life Sciences [q-bio]/Cancer, PROGNOSTIC SCORING SYSTEM, DIAGNOSIS, CYTOGENETICS, myelodysplastic syndromes, CLASSIFICATION, VALIDATION, All institutes and research themes of the Radboud University Medical Center, [SDV.CAN] Life Sciences [q-bio]/Cancer, consensus, hemic and lymphatic diseases, CELLS, SUBGROUPS, ELN, CYTOMORPHOLOGY
Abstract

Contains fulltext : 290800.pdf (Publisher’s version ) (Open Access) This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients. 01 januari 2023

Published
2023

17. Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group

Author

Kern, Wolfgang, primary, Westers, Theresia M., additional, Bellos, Frauke, additional, Bene, Marie Christine, additional, Bettelheim, Peter, additional, Brodersen, Lisa Eidenschink, additional, Burbury, Kate, additional, Chu, Sung‐Chao, additional, Cullen, Matthew, additional, Porta, Matteo Della, additional, Dunlop, Alan Stewart, additional, Johansson, Ulrika, additional, Matarraz, Sergio, additional, Oelschlaegel, Uta, additional, Ogata, Kiyoyuki, additional, Porwit, Anna, additional, Preijers, Frank, additional, Psarra, Katherina, additional, Saft, Leonie, additional, Subirá, Dolores, additional, Weiß, Elisabeth, additional, van der Velden, Vincent H. J., additional, and van de Loosdrecht, Arjan, additional

Published
2022
Full Text
View/download PDF

20. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen

Author

Österreichische Gesellschaft Für Hämatologie & Medizinische Onkologie, Schweizerische Gesellschaft Für Hämatologie, Stüssi, Georg, Bettelheim, Peter, Schrezenmeier, Hubert, Schweizerische Gesellschaft Für Medizinische Onkologie, Höchsmann, Britta Elisabeth Hedwig, Panse, Jens, Röth, Alexander, Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, Brümmendorf, Tim Henrik, and Schubert, Jörg

Subjects
Medizin und Gesundheit
Published
2022
Full Text
View/download PDF

21. PD‐L1 overexpression correlates withJAK2 ‐V617Fmutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms

Author

Milosevic Feenstra, Jelena D., primary, Jäger, Roland, additional, Schischlik, Fiorella, additional, Ivanov, Daniel, additional, Eisenwort, Gregor, additional, Rumi, Elisa, additional, Schuster, Michael, additional, Gisslinger, Bettina, additional, Machherndl‐Spandl, Sigrid, additional, Bettelheim, Peter, additional, Krauth, Maria‐Theresa, additional, Keil, Felix, additional, Bock, Christoph, additional, Cazzola, Mario, additional, Gisslinger, Heinz, additional, Kralovics, Robert, additional, and Valent, Peter, additional

Published
2022
Full Text
View/download PDF

22. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS‐Flow Cytometry Working Group

Author

van de Loosdrecht, Arjan A., primary, Kern, Wolfgang, additional, Porwit, Anna, additional, Valent, Peter, additional, Kordasti, Sharham, additional, Cremers, Eline, additional, Alhan, Canan, additional, Duetz, Carolien, additional, Dunlop, Alan, additional, Hobo, Willemijn, additional, Preijers, Frank, additional, Wagner‐Ballon, Orianne, additional, Chapuis, Nicolas, additional, Fontenay, Michaela, additional, Bettelheim, Peter, additional, Eidenschink‐Brodersen, Lisa, additional, Font, Patricia, additional, Johansson, Ulrika, additional, Loken, Michael R., additional, te Marvelde, Jeroen G., additional, Matarraz, Sergio, additional, Ogata, Kiyoyuki, additional, Oelschlaegel, Uta, additional, Orfao, Alberto, additional, Psarra, Katherina, additional, Subirá, Dolores, additional, Wells, Denise A., additional, Béné, Marie C., additional, Della Porta, Matteo G., additional, Burbury, Kate, additional, Bellos, Frauke, additional, van der Velden, Vincent H. J., additional, Westers, Theresia M., additional, Saft, Leonie, additional, and Ireland, Robin, additional

Published
2021
Full Text
View/download PDF

23. Flow cytometric analysis of myelodysplasia: Pre‐analytical and technical issues—Recommendations from the European LeukemiaNet

Author

van der Velden, Vincent H. J., primary, Preijers, Frank, additional, Johansson, Ulrika, additional, Westers, Theresia M., additional, Dunlop, Alan, additional, Porwit, Anna, additional, Béné, Marie C., additional, Valent, Peter, additional, te Marvelde, Jeroen, additional, Wagner‐Ballon, Orianne, additional, Oelschlaegel, Uta, additional, Saft, Leonie, additional, Kordasti, Sharham, additional, Ireland, Robin, additional, Cremers, Eline, additional, Alhan, Canan, additional, Duetz, Carolien, additional, Hobo, Willemijn, additional, Chapuis, Nicolas, additional, Fontenay, Michaela, additional, Bettelheim, Peter, additional, Eidenshink‐Brodersen, Lisa, additional, Font, Patricia, additional, Loken, Michael R., additional, Matarraz, Sergio, additional, Ogata, Kiyoyuki, additional, Orfao, Alberto, additional, Psarra, Katherina, additional, Subirá, Dolores, additional, Wells, Denise A., additional, Della Porta, Matteo G., additional, Burbury, Kate, additional, Bellos, Frauke, additional, Weiß, Elisabeth, additional, Kern, Wolfgang, additional, and van de Loosdrecht, Arjan, additional

Published
2021
Full Text
View/download PDF

24. ELN iMDS flow working group validation of the monocyte assay for chronic myelomonocytic leukemia diagnosis by flow cytometry.

Author

Wagner‐Ballon, Orianne, Bettelheim, Peter, Lauf, Jeroen, Bellos, Frauke, Della Porta, Matteo, Travaglino, Erica, Subira, Dolores, Lopez, Irene Nuevo, Tarfi, Sihem, Westers, Theresia M., Johansson, Ulrika, Psarra, Katherina, Karathanos, Serafeim, Matarraz, Sergio, Colado, Enrique, Gupta, Monali, Ireland, Robin, Kern, Wolfgang, and Van De Loosdrecht, Arjan A.

Published
2023
Full Text
View/download PDF

25. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS‐Flow Cytometry Working Group.

Author

van de Loosdrecht, Arjan A., Kern, Wolfgang, Porwit, Anna, Valent, Peter, Kordasti, Sharham, Cremers, Eline, Alhan, Canan, Duetz, Carolien, Dunlop, Alan, Hobo, Willemijn, Preijers, Frank, Wagner‐Ballon, Orianne, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink‐Brodersen, Lisa, Font, Patricia, Johansson, Ulrika, Loken, Michael R., and te Marvelde, Jeroen G.

Published
2023
Full Text
View/download PDF

26. ELN IMDS Flow Working Group Validation of the Monocyte Assay for Chronic Myelomonocytic Leukemia Diagnosis By Flow Cytometry

Author

Wagner-Ballon, Orianne, primary, Bettelheim, Peter, additional, Lauf, Jeroen, additional, Bellos, Frauke, additional, Della Porta, Matteo G., additional, Travaglino, Erica, additional, Subirá, Dolores, additional, Nuevo, Irene, additional, Tarfi, Sihem, additional, Westers, Theresia M., additional, Johansson, Ulrika, additional, Psarra, Katherina, additional, Karathanos, Serafeim, additional, Matarraz, Sergio, additional, Colado, Enrique, additional, Gupta, Monali, additional, Ireland, Robin M., additional, Kern, Wolfgang, additional, and van de Loosdrecht, Arjan, additional

Published
2021
Full Text
View/download PDF

27. Multicenter Prospective Evaluation of Diagnostic Potential of Flow Cytometric Aberrancies in Myelodysplastic Syndromes

Author

Kern, Wolfgang, primary, Westers, Theresia M., additional, Bellos, Frauke, additional, Bene, Marie C, additional, Bettelheim, Peter, additional, Eidenschink Brodersen, Lisa, additional, Burbury, Kate, additional, Chu, Sung-Chao, additional, Cullen, Matthew, additional, Porta, Matteo Della, additional, Dunlop, Alan Stewart, additional, Johansson, Ulrika, additional, Matarraz, Sergio, additional, Oelschlaegel, Uta, additional, Ogata, Kiyoyuki, additional, Porwit, Anna, additional, Preijers, Frank W. M. B., additional, Psarra, Katherina, additional, Saft, Leonie, additional, Subirá, Dolores, additional, Weiss, Elisabeth, additional, and Van de Loosdrecht, Arjan A., additional

Published
2021
Full Text
View/download PDF

28. Veranstaltungen

Author

Feichtinger, Gustav, Münz, R., Bettelheim, Peter, Benedikter, Rudi, Ernst, Andrea, Kischke, Martina, Gisser, Richard, and Schwarz, Karl

Published
1982

30. Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies.

Author

Kulasekararaj, Austin G., Griffin, Morag, Langemeijer, Saskia, Usuki, Kensuke, Kulagin, Alexander, Ogawa, Masayo, Yu, Ji, Mujeebuddin, Arshad, Nishimura, Jun‐ichi, Lee, Jong Wook, Peffault de Latour, Régis, Latypova, Aigul, Barcellini, Wilma, Barraco, Fiorenza, Beam, Donald, Bettelheim, Peter, Borisenkova, Elena, Brodsky, Andres, Carnley, Benedict, and Cermak, Jaroslav

Subjects
PAROXYSMAL hemoglobinuria, LACTATE dehydrogenase
Abstract

Objectives: The complement component 5 (C5) inhibitor ravulizumab demonstrated non‐inferiority to eculizumab following 26 weeks of treatment in complement inhibitor‐naïve and complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria (PNH; studies 301 and 302, respectively). This study aims to describe the results of both studies from 27 weeks to 2 years. Methods: Patients (N = 441) continued to receive ravulizumab throughout the extension period. Efficacy endpoints included lactate dehydrogenase (LDH) normalization, transfusion avoidance and fatigue score (FACIT‐F). Safety analyses were also performed. Results: From 27 weeks to 2 years, improvements in LDH levels were maintained in both study populations. Transfusion avoidance was maintained in 81.9% (study 301) and 85.6% (study 302) of patients, and FACIT‐F scores remained stable. Ravulizumab was well tolerated, and the incidence of adverse events (AEs) were similar between patients of both studies. Incidence of serious AEs deemed related to ravulizumab treatment was low (<3%). Conclusions: This study reports, to date, the longest period of follow‐up in over 400 patients with PNH treated with ravulizumab (662 patient‐years). Long‐term, ravulizumab demonstrated durable efficacy and was well tolerated, highlighting the importance of C5 inhibitors as the mainstay of PNH treatment. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

31. Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia

Author

Machherndl‐Spandl, Sigrid, primary, Jäger, Eva, additional, Barna, Agnes, additional, Gurbisz, Michael, additional, Marschon, Renate, additional, Graf, Temeida, additional, Graf, Elmir, additional, Geissler, Christoph, additional, Hoermann, Gregor, additional, Nösslinger, Thomas, additional, Pfeilstöcker, Michael, additional, Bettelheim, Peter, additional, Zach, Otto, additional, Weltermann, Ansgar, additional, Heibl, Sonja, additional, Thaler, Josef, additional, Zebisch, Armin, additional, Sill, Heinz, additional, Stauder, Reinhard, additional, Webersinke, Gerald, additional, Kusec, Rajko, additional, Ulsperger, Ernst, additional, Schneeweiss, Bruno, additional, Öhler, Leopold, additional, Germing, Ulrich, additional, Valent, Peter, additional, Tüchler, Heinz, additional, and Geissler, Klaus, additional

Published
2021
Full Text
View/download PDF

32. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie h��matologischer und onkologischer Erkrankungen

Author

��sterreichische Gesellschaft F��r H��matologie & Medizinische Onkologie, Schweizerische Gesellschaft F��r H��matologie, Rov��, Alicia, Bettelheim, Peter, Rosenwald, Andreas, Haferlach, Torsten, Schweizerische Gesellschaft F��r Medizinische Onkologie, Kreuzer, Karl-Anton, Deutsche Gesellschaft F��r H��matologie Und Medizinische Onkologie, and Schanz, Julie

Subjects
Medizin und Gesundheit
Published
2021
Full Text
View/download PDF

33. Meeting report: Vienna 2008 Workshop of the German–Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes

Author

Valent, Peter, Hofmann, Wolf-Karsten, Büsche, Guntram, Sotlar, Karl, Horny, Hans-Peter, Haase, Detlef, Haferlach, Torsten, Kern, Wolfgang, Bettelheim, Peter, Baumgartner, Christian, Sperr, Wolfgang R., Nösslinger, Thomas, Wimazal, Friedrich, Giagounidis, Aristoteles A., Lübbert, Michael, Krieger, Otto, Kolb, Hans-Jochem, Stauder, Reinhard, Pfeilstöcker, Michael, Gattermann, Norbert, Fonatsch, Christa, Aul, Carlo, and Germing, Ulrich

Published
2009
Full Text
View/download PDF

34. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues

Author

Porwit, Anna, Béné, Marie C., Duetz, Carolien, Matarraz, Sergio, Oelschlaegel, Uta, Westers, Theresia M., Wagner‐Ballon, Orianne, Kordasti, Shahram, Valent, Peter, Preijers, Frank, Alhan, Canan, Bellos, Frauke, Bettelheim, Peter, Burbury, Kate, Chapuis, Nicolas, Cremers, Eline, Della Porta, Matteo G., Dunlop, Alan, Eidenschink‐Brodersen, Lisa, Font, Patricia, Fontenay, Michaela, Hobo, Willemijn, Ireland, Robin, Johansson, Ulrika, Loken, Michael R., Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Saft, Leonie, Subira, Dolores, Marvelde, Jeroen, Wells, Denise A., Velden, Vincent H. J., Kern, Wolfgang, and Loosdrecht, Arjan A.

Abstract

Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic syndrome (MDS). MFC can also be applied in the follow‐up of MDS patients undergoing treatment. This document summarizes recommendations from the International/European Leukemia Net Working Group for Flow Cytometry in Myelodysplastic Syndromes (ELN iMDS Flow) on the analytical issues in MFC for the diagnostic work‐up of MDS. Recommendations for the analysis of several BM cell subsets such as myeloid precursors, maturing granulocytic and monocytic components and erythropoiesis are given. A core set of 17 markers identified as independently related to a cytomorphologic diagnosis of myelodysplasia is suggested as mandatory for MFC evaluation of BM in a patient with cytopenia. A myeloid precursor cell (CD34+CD19−) count >3% should be considered immunophenotypically indicative of myelodysplasia. However, MFC results should always be evaluated as part of an integrated hematopathology work‐up. Looking forward, several machine‐learning‐based analytical tools of interest should be applied in parallel to conventional analytical methods to investigate their usefulness in integrated diagnostics, risk stratification, and potentially even in the evaluation of response to therapy, based on MFC data. In addition, compiling large uniform datasets is desirable, as most of the machine‐learning‐based methods tend to perform better with larger numbers of investigated samples, especially in such a heterogeneous disease as MDS.

Published
2023
Full Text
View/download PDF

35. Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDSflow working group

Author

Kern, Wolfgang, Westers, Theresia M., Bellos, Frauke, Bene, Marie Christine, Bettelheim, Peter, Brodersen, Lisa Eidenschink, Burbury, Kate, Chu, Sung‐Chao, Cullen, Matthew, Porta, Matteo Della, Dunlop, Alan Stewart, Johansson, Ulrika, Matarraz, Sergio, Oelschlaegel, Uta, Ogata, Kiyoyuki, Porwit, Anna, Preijers, Frank, Psarra, Katherina, Saft, Leonie, Subirá, Dolores, Weiß, Elisabeth, Velden, Vincent H. J., and Loosdrecht, Arjan

Abstract

Myelodysplastic syndromes (MDS) represent a diagnostic challenge. This prospective multicenter study was conducted to evaluate pre‐defined flow cytometric markers in the diagnostic work‐up of MDS and chronic myelomonocytic leukemia (CMML). Thousand six hundred and eighty‐two patients with suspected MDS/CMML were analyzed by both cytomorphology according to WHO 2016 criteria and flow cytometry according to ELN recommendations. Flow cytometric readout was categorized ‘non‐MDS’ (i.e. no signs of MDS/CMML and limited signs of MDS/CMML) and ‘in agreement with MDS’ (i.e., in agreement with MDS/CMML). Flow cytometric readout categorized 60% of patients in agreement with MDS, 28% showed limited signs of MDS and 12% had no signs of MDS. In 81% of cases flow cytometric readouts and cytomorphologic diagnosis correlated. For high‐risk MDS, the level of concordance was 92%. A total of 17 immunophenotypic aberrancies were found independently related to MDS/CMML in ≥1 of the subgroups of low‐risk MDS, high‐risk MDS, CMML. A cut‐off of ≥3 of these aberrancies resulted in 80% agreement with cytomorphology (20% cases concordantly negative, 60% positive). Moreover, >3% myeloid progenitor cells were significantly associated with MDS (286/293 such cases, 98%). Data from this prospective multicenter study led to recognition of 17 immunophenotypic markers allowing to identify cases ‘in agreement with MDS’. Moreover, data emphasizes the clinical utility of immunophenotyping in MDS diagnostics, given the high concordance between cytomorphology and the flow cytometric readout. Results from the current study challenge the application of the cytomorphologically defined cut‐off of 5% blasts for flow cytometry and rather suggest a 3% cut‐off for the latter.

Published
2023
Full Text
View/download PDF

36. Flow cytometric analysis of myelodysplasia: Pre‐analytical and technical issues—Recommendations from the European LeukemiaNet

Author

Velden, Vincent H. J., Preijers, Frank, Johansson, Ulrika, Westers, Theresia M., Dunlop, Alan, Porwit, Anna, Béné, Marie C., Valent, Peter, Marvelde, Jeroen, Wagner‐Ballon, Orianne, Oelschlaegel, Uta, Saft, Leonie, Kordasti, Sharham, Ireland, Robin, Cremers, Eline, Alhan, Canan, Duetz, Carolien, Hobo, Willemijn, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenshink‐Brodersen, Lisa, Font, Patricia, Loken, Michael R., Matarraz, Sergio, Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, Weiß, Elisabeth, Kern, Wolfgang, and Loosdrecht, Arjan

Abstract

Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre‐analytical procedures. Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.

Published
2023
Full Text
View/download PDF

37. ELN iMDSflow working group validation of the monocyte assay for chronic myelomonocytic leukemia diagnosis by flow cytometry

Author

Wagner‐Ballon, Orianne, Bettelheim, Peter, Lauf, Jeroen, Bellos, Frauke, Della Porta, Matteo, Travaglino, Erica, Subira, Dolores, Lopez, Irene Nuevo, Tarfi, Sihem, Westers, Theresia M., Johansson, Ulrika, Psarra, Katherina, Karathanos, Serafeim, Matarraz, Sergio, Colado, Enrique, Gupta, Monali, Ireland, Robin, Kern, Wolfgang, and Van De Loosdrecht, Arjan A.

Abstract

Background:It was proposed that peripheral blood (PB) monocyte profiles evaluated by flow cytometry, called “monocyte assay,” could rapidly and efficiently distinguish chronic myelomonocytic leukemia (CMML) from other causes of monocytosis by highlighting an increase in the classical monocyte (cMo) fraction above 94%. However, the robustness of this assay requires a large multicenter validation and the assessment of its feasibility on bone marrow (BM) samples, as some centers may not have access to PB. Methods:PB and/or BM samples from patients displaying monocytosis were assessed with the “monocyte assay” by 10 ELN iMDS Flow working group centers with harmonized protocols. The corresponding files were reanalyzed in a blind fashion and the cMo percentages obtained by both analyses were compared. Confirmed diagnoses were collected when available. Results:The comparison between cMo percentages from 267 PB files showed a good global significant correlation (r= 0.88) with no bias. Confirmed diagnoses, available for 212 patients, achieved a 94% sensitivity and an 84% specificity. Hence, 95/101 CMML patients displayed cMo ≥94% while cMo <94% was observed in 83/99 patients with reactive monocytosis and in 10/12 patients with myeloproliferative neoplasms (MPN) with monocytosis. The established Receiver Operator Curve again provided a 94% cut‐off value of cMo. The 117 BM files reanalysis led to an 87% sensitivity and an 80% specificity, with excellent correlation between the 43 paired samples to PB. Conclusions:This ELN multicenter study demonstrates the robustness of the monocyte assay with only limited variability of cMo percentages, validates the 94% cutoff value, confirms its high sensitivity and specificity in PB and finally, also confirms the possibility of its use in BM samples.

Published
2023
Full Text
View/download PDF

38. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNetInternational MDS‐FlowCytometry Working Group

Author

Loosdrecht, Arjan A., Kern, Wolfgang, Porwit, Anna, Valent, Peter, Kordasti, Sharham, Cremers, Eline, Alhan, Canan, Duetz, Carolien, Dunlop, Alan, Hobo, Willemijn, Preijers, Frank, Wagner‐Ballon, Orianne, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink‐Brodersen, Lisa, Font, Patricia, Johansson, Ulrika, Loken, Michael R., Marvelde, Jeroen G., Matarraz, Sergio, Ogata, Kiyoyuki, Oelschlaegel, Uta, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Béné, Marie C., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, Velden, Vincent H. J., Westers, Theresia M., Saft, Leonie, and Ireland, Robin

Abstract

This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow‐up of MDS patients.

Published
2023
Full Text
View/download PDF

39. PD‐L1 overexpression correlates with JAK2‐V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms.

Author

Milosevic Feenstra, Jelena D., Jäger, Roland, Schischlik, Fiorella, Ivanov, Daniel, Eisenwort, Gregor, Rumi, Elisa, Schuster, Michael, Gisslinger, Bettina, Machherndl‐Spandl, Sigrid, Bettelheim, Peter, Krauth, Maria‐Theresa, Keil, Felix, Bock, Christoph, Cazzola, Mario, Gisslinger, Heinz, Kralovics, Robert, and Valent, Peter

Published
2022
Full Text
View/download PDF

40. Phenotyping of Disease-Initiating CD34+/CD38─ Stem Cells in BCR-ABL1─ MPN Reveals Expression of Multiple Cytokine Receptors and Resistance-Related Antigens

Author

Ivanov, Daniel, primary, Milosevic Feenstra, Jelena D., additional, Eisenwort, Gregor, additional, Spörk, Robert, additional, Keller, Alexandra, additional, Peter, Barbara, additional, Willmann, Michael, additional, Greiner, Georg, additional, Stefanzl, Gabriele, additional, Slavnitsch, Katharina, additional, Hoermann, Gregor, additional, Hofer, Sybille, additional, Sperr, Wolfgang R., additional, Sill, Heinz, additional, Bettelheim, Peter, additional, Geissler, Klaus, additional, Koller, Elisabeth, additional, Fillitz, Michael, additional, Pfeilstocker, Michael, additional, Rülicke, Thomas, additional, Sliwa, Thamer, additional, Keil, Felix, additional, Kralovics, Robert, additional, and Valent, Peter, additional

Published
2020
Full Text
View/download PDF

41. Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype

Author

Heibl, Sonja, primary, Gisslinger, Bettina, additional, Jäger, Eva, additional, Barna, Agnes, additional, Gurbisz, Michael, additional, Stegemann, Maike, additional, Bettelheim, Peter, additional, Machherndl-Spandl, Sigrid, additional, Pfeilstöcker, Michael, additional, Nösslinger, Thomas, additional, Uyanik, Gökhan, additional, Hoermann, Gregor, additional, Stauder, Reinhard, additional, Thaler, Josef, additional, Kusec, Rajko, additional, Valent, Peter, additional, Gisslinger, Heinz, additional, and Geissler, Klaus, additional

Published
2020
Full Text
View/download PDF

42. Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia—A Retrospective Analysis in 337 Patients

Author

Geissler, Klaus, primary, Jäger, Eva, additional, Barna, Agnes, additional, Gurbisz, Michael, additional, Graf, Temeida, additional, Graf, Elmir, additional, Nösslinger, Thomas, additional, Pfeilstöcker, Michael, additional, Tüchler, Heinz, additional, Sliwa, Thamer, additional, Keil, Felix, additional, Geissler, Christoph, additional, Heibl, Sonja, additional, Thaler, Josef, additional, Machherndl-Spandl, Sigrid, additional, Zach, Otto, additional, Weltermann, Ansgar, additional, Bettelheim, Peter, additional, Stauder, Reinhard, additional, Zebisch, Armin, additional, Sill, Heinz, additional, Schwarzinger, Ilse, additional, Schneeweiss, Bruno, additional, Öhler, Leopold, additional, Ulsperger, Ernst, additional, Kusec, Rajko, additional, Germing, Ulrich, additional, Sperr, Wolfgang R., additional, Knöbl, Paul, additional, Jäger, Ulrich, additional, Hörmann, Gregor, additional, and Valent, Peter, additional

Published
2020
Full Text
View/download PDF

43. A European consensus report on blood cell identification: terminology utilized and morphological diagnosis concordance among 28 experts from 17 countries within the European LeukemiaNet network WP10, on behalf of the ELN Morphology Faculty

Author

Zini, Gina, Bain, Barbara, Bettelheim, Peter, Cortez, José, DʼOnofrio, Giuseppe, Faber, Edgar, Haferlach, Torsten, Kacirkova, Petra, Lewandowski, Krzysztof, Matutes, Estella, Maynadié, Marc, Meletis, John, Petersen, Bodil L., Porwit, Anna, Terpos, Evangelos, Tichelli, Andrée, Vallespí, Teresa, Woessner, Soledad, Bennett, John, and Bene, Marie C.

Published
2010
Full Text
View/download PDF

46. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen

Author

Österreichische Gesellschaft Für Hämatologie & Medizinische Onkologie, Schweizerische Gesellschaft Für Hämatologie, Bettelheim, Peter, Rosenwald, Andreas, Haferlach, Torsten, Schweizerische Gesellschaft Für Medizinische Onkologie, Kreuzer, Karl-Anton, and Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie

Subjects
Medizin und Gesundheit
Published
2018
Full Text
View/download PDF

47. Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML)

Author

Eisenwort, Gregor, primary, Keller, Alexandra, additional, Willmann, Michael, additional, Sadovnik, Irina, additional, Georg, Greiner, additional, Gleixner, Karoline V., additional, Ivanov, Daniel, additional, Berger, Daniela, additional, Stefanzl, Gabriele, additional, Winding, Christiana, additional, Hoermann, Gregor, additional, Sperr, Wolfgang R., additional, Sill, Heinz, additional, Bettelheim, Peter, additional, Geissler, Klaus, additional, Deininger, Michael W., additional, Rülicke, Thomas, additional, and Valent, Peter, additional

Published
2019
Full Text
View/download PDF

50. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions

Author

Valent, Peter, Orazi, Attilio, Steensma, David P., Ebert, Benjamin L., Haase, Detlef, Malcovati, Luca, van de Loosdrecht, Arjan A., Haferlach, Torsten, Westers, Theresia M., Wells, Denise A., Giagounidis, Aristoteles, Loken, Michael, Orfao, Alberto, Lübbert, Michael, Ganser, Arnold, Hofmann, Wolf Karsten, Ogata, Kiyoyuki, Schanz, Julie, Béné, Marie C., Hoermann, Gregor, Sperr, Wolfgang R., Sotlar, Karl, Bettelheim, Peter, Stauder, Reinhard, Pfeilstöcker, Michael, Horny, Hans Peter, Germing, Ulrich, Greenberg, Peter, Bennett, John M., Medical University of Vienna, and Austrian Science Fund

Subjects
Diagnostic criteria, Pre-MDS conditions, myelodysplasia, diagnostic criteria, standardization, pre-MDS conditions, hemic and lymphatic diseases, Myelodysplasia, Priority Review, Standardization
Abstract

Myelodysplastic syndromes (MDS) comprise a heterogeneous group of myeloid neoplasms characterized by peripheral cytopenia, dysplasia, and a variable clinical course with about 30% risk to transform to secondary acute myeloid leukemia (AML). In the past 15 years, diagnostic evaluations, prognostication, and treatment of MDS have improved substantially. However, with the discovery of molecular markers and advent of novel targeted therapies, new challenges have emerged in the complex field of MDS. For example, MDS-related molecular lesions may be detectable in healthy individuals and increase in prevalence with age. Other patients exhibit persistent cytopenia of unknown etiology without dysplasia. Although these conditions are potential pre-phases of MDS they may also transform into other bone marrow neoplasms. Recently identified molecular, cytogenetic, and flow-based parameters may add in the delineation and prognostication of these conditions. However, no generally accepted integrated classification and no related criteria are as yet available. In an attempt to address this challenge, an international consensus group discussed these issues in a working conference in July 2016. The outcomes of this conference are summarized in the present article which includes criteria and a proposal for the classification of pre-MDS conditions as well as updated minimal diagnostic criteria of MDS. Moreover, we propose diagnostic standards to delineate between 'normal', pre-MDS, and MDS. These standards and criteria should facilitate diagnostic and prognostic evaluations in clinical studies as well as in clinical practice., This study was supported by the Austrian Science Fund (FWF) grant F4704-B20 and a Stem Cell Research Grant of the Medical University of Vienna.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results